World Bulletin/News Desk
The World Health Organization has endorsed using HIV medicines among people who do not have the infection but are at high risk of getting it, and suggested that poor and wealthy countries alike set up pilot projects to better understand the benefits.
The United Nations agency made its suggestion on Friday, four days after U.S. regulators approved use of Gilead Sciences Inc's Truvada for people who are not infected but may engage in sexual activity with HIV-positive partners. The concept is known as pre-exposure prophylaxis (PrEP).
Truvada, which combines the anti-HIV drugs tenofovir and emtricitabine in one pill, is widely used to treat people already infected with the virus that causes AIDS. The medicine, which costs almost $14,000 a year in the United States, is the first treatment also approved for prevention.
"WHO is encouraging countries wishing to introduce PrEP to first establish small projects to help public health workers to better understand and realize its potential benefits," the agency said in a statement. It said appropriate HIV medicines should be given to those at high risk of infection.
"These could include men or transgender women who have sex with men," the group said.
WHO spokeswoman Sarah Russell said the agency could not recommend specific drugs for prevention, but she said, "It needs to be a drug like Truvada that has been developed for prevention purposes."
Russell said WHO expects Gilead to make Truvada available at a deeply discounted price in some poor countries.
"We believe Gilead will bring the price down to about $100 per year per person" in those countries, she said in an interview.
Gilead officials could not immediately be reached for comment.
WHO noted that an international study called Partners PrEP has shown that HIV medicines are highly effective at preventing the illness in men and women whose partners are infected.
That study, conducted in Kenya and Uganda and funded by the Bill & Melinda Gates Foundation, involved taking a daily tablet containing tenofovir or tenofovir in combination with emtricitabine.
The U.N. agency said it would evaluate the outcomes of the small projects, along with evolving scientific evidence, before issuing its own detailed guidelines next year on the use of HIV treatments for prevention.
WHO said it was important that people taking HIV drugs for prevention are HIV-negative because otherwise drug resistant forms of HIV could evolve. The agency said they should also continue using condoms and faithfully take their medicines on a daily basis.
'Protecting human rights is key to responding to the Ebola outbreak,' HRW says
World Health Organization and Public Health Ministry on May 8 announced confirmed cases of Ebola in the country
Ebola outbreak in Democratic Republic of Congo is a 'wake-up call,' says head of West African Health Organization
Tobacco use is falling, but not fast enough, with active or passive smoking killing over 7 million people every year
Slogan for this year's campaign is 'Time to see beauties'
Developed by high school students in west Turkey, microchip gets award in US, Europe
UN reports cases of Ebola virus disease 'in an urban center' that killed 25 so far
In a statement, the UN agency said WHO Director General Tedros Adhanom Ghebreyesus would convene an emergency committee to discuss the matter.
Following is a recap of past epidemics of Ebola as the Democratic Republic of Congo (DRC) battles a new outbreak of the deadly tropical disease:
In the absence of rules, travel agencies offer trips to the region on boats sometimes equipped with helicopters or submarines, according to Segolene Royal, French ambassador for the Arctic and Antarctic poles.
Three health care workers among 19 deaths, World Health Organization says
World Health Organization concerned about potential regional spread of deadly virus
Doctors Worldwide provides orthopaedic training to health personnel
People suffering from advanced cardiac or pulmonary insufficiency to benefit from device made at university in Izmir